Research demonstrates that socioeconomic inequalities are "strong determinants" of cardiovascular risk throughout the world.
Members of the writing committee for the American College of Cardiology/American Heart Association 2019 Guideline on Primary Prevention of Cardiovascular Disease incorporated throughout the guideline consideration of how social determinants of health may impact the efficacy of specific guidance and prescriptions for an individual patient. ACC/AHA recommends that clinicians revisit these considerations at each follow-up visit.
Considerations include but are not limited to socioeconomic and educational status as well as cultural, home, and employment environments. The slides below highlight examples of considerations cited by the ACC/AHA for 7 health domains.
Social Determinants of Health and Prevention of Cardiovascular Disease
Research demonstrates that socioeconomic inequalities are "strong determinants" of cardiovascular risk throughout the world.
Members of the writing committee for the American College of Cardiology/American Heart Association 2019 Guideline on Primary Prevention of Cardiovascular Disease incorporated throughout the guideline consideration of how social determinants of health may impact the efficacy of specific guidance and prescriptions for an individual patient. ACC/AHA recommends that clinicians revisit these considerations at each follow-up visit.
Considerations include but are not limited to socioeconomic and educational status as well as cultural, home, and employment environments. The slides below highlight examples of considerations cited by the ACC/AHA for 7 health domains.
Daily Dose: Waist-to-Hip Ratio Better Predictor for Mortality than BMI?
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
One or More Cardiac, Renal, or Metabolic Conditions Affect 25% of US Adults
Obesity & Type 2 Diabetes: An Expert Discussion
Investigational Nasal Spray Found Safe, Effective for Self-Treatment of Paroxysmal Supraventricular Tachycardia
GLP-1 Mimetics, SGLT-2 Inhibitors Understudied in Black Populations in Pivotal Trials, Benefits Questioned
Daily Dose: Waist-to-Hip Ratio Better Predictor for Mortality than BMI?
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
One or More Cardiac, Renal, or Metabolic Conditions Affect 25% of US Adults
Obesity & Type 2 Diabetes: An Expert Discussion
Investigational Nasal Spray Found Safe, Effective for Self-Treatment of Paroxysmal Supraventricular Tachycardia
GLP-1 Mimetics, SGLT-2 Inhibitors Understudied in Black Populations in Pivotal Trials, Benefits Questioned
Daily Dose: Waist-to-Hip Ratio Better Predictor for Mortality than BMI?
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
One or More Cardiac, Renal, or Metabolic Conditions Affect 25% of US Adults
Obesity & Type 2 Diabetes: An Expert Discussion
Investigational Nasal Spray Found Safe, Effective for Self-Treatment of Paroxysmal Supraventricular Tachycardia
GLP-1 Mimetics, SGLT-2 Inhibitors Understudied in Black Populations in Pivotal Trials, Benefits Questioned
Daily Dose: Waist-to-Hip Ratio Better Predictor for Mortality than BMI?
September 29th 2023Your daily dose of the clinical news you may have missed.
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
August 30th 2023Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.
One or More Cardiac, Renal, or Metabolic Conditions Affect 25% of US Adults
September 29th 2023The prevalence of cardiac, renal, and metabolic conditions has significantly increased over 20 years and so has the number of US adults who have all 3.
Obesity & Type 2 Diabetes: An Expert Discussion
June 30th 2023In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.
Investigational Nasal Spray Found Safe, Effective for Self-Treatment of Paroxysmal Supraventricular Tachycardia
September 27th 2023Etripamil 70 mg nasal spray restored heart rate within 30 minutes in approximately 60% of PSVT episodes, report authors of new study.
GLP-1 Mimetics, SGLT-2 Inhibitors Understudied in Black Populations in Pivotal Trials, Benefits Questioned
September 26th 2023Pivotal cardiovascular outcome trials that evaluated cardiorenal benefits of the newer classes were not designed to consider racial/ethnic variations, researchers state.